The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
High Avidity CTLs for Two Self-Antigens Demonstrate Superior In Vitro and In Vivo Antitumor Efficacy
Abstract
A majority of the human tumor-associated Ags characterized to date are derived from nonmutated “self”-proteins. Little is currently understood about the nature of the self-reactive lymphocytes that recognize these Ags. We recently characterized two nonmutated tumor-associated Ags for the B16 murine melanoma: tyrosinase-related protein-2 (TRP-2) and the endogenous retroviral envelope protein, p15E. We previously reported that both TRP-2 and p15E reactive CTL could be detected in the spleens of naive animals after a single in vitro stimulation using 10−5–10−6 M of the appropriate Kb-binding 9-amino acid epitope. In this report we show that the CTL found in naive animals are low avidity lymphocytes, that respond only to high concentrations of peptide in vitro. We demonstrate that titration of in vitro-stimulating peptide to limiting concentrations distinguishes qualitative differences in the lymphocyte reactivity to these two Ags between vaccinated and unvaccinated animals. We further demonstrate that in vitro expansion of CTL in either high or low concentrations of stimulating peptide generated CTL cultures with different avidities for the relevant epitopes. CTL expanded in low concentrations demonstrated higher avidity for peptide-pulsed targets and better tumor recognition, when compared to CTL generated in the presence of high concentrations of Ag. More importantly, high avidity CTL demonstrated superior in vivo antitumor activity. These results demonstrate that qualitative differences in the CTL that recognize these two self-Ags are critically important to their in vitro and in vivo anti-tumor efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Dudley, M. E., Schwarz, S. L., Spiess, P. J., et al. (1998) · Nature Medicine · doi:10.1038/nm0398-321 · Cited by 1,784
Self-citationThe Duration of Antigenic Stimulation Determines the Fate of Naive and Effector T Cells
Iezzi, G., Karjalainen, K., & Lanzavecchia, A. (1998) · Immunity · doi:10.1016/s1074-7613(00)80461-6 · Cited by 908
Kawakami, Y., Eliyahu, S., Jennings, C., Sakaguchi, K., Kang, X., Southwood, S., Robbins, P. F., Sette, A., Appella, E., & Rosenberg, S. A. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.8.3961 · Cited by 540
Self-citationT Cell Deletion in High Antigen Dose Therapy of Autoimmune Encephalomyelitis
Critchfield, J. M., Racke, M. K., Zúñiga-Pflücker, J. C., Cannella, B., Raine, C. S., Goverman, J., & Lenardo, M. J. (1994) · Science · doi:10.1126/science.7509084 · Cited by 524
Alexander-Miller, M. A., Leggatt, G. R., & Berzofsky, J. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.9.4102 · Cited by 501
Barth, R. J., Mulé, J. J., Spiess, P. J., & Rosenberg, S. A. (1991) · The Journal of experimental medicine · doi:10.1084/jem.173.3.647 · Cited by 402
Self-citationIdentification of Tyrosinase-related Protein 2 as a Tumor Rejection Antigen for the B16 Melanoma
Bloom, M. B., Perry-Lalley, D., Robbins, P. F., Li, Y., El-Gamil, M., Rosenberg, S. A., & Yang, J. C. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.3.453 · Cited by 401
Self-citationPeptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction.
Toes, R. E., Offringa, R., Blom, R. J., Melief, C. J., & Kast, W. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.15.7855 · Cited by 292
Alexander-Miller, M. A., Leggatt, G. R., Sarin, A., & Berzofsky, J. A. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.2.485 · Cited by 222
Toes, R. E., Blom, R. J., Offringa, R., Kast, W. M., & Melief, C. J. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.10.3911 · Cited by 208
Cited by
Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy
Morgan, R. A., Chinnasamy, N., Abate-Daga, D., Gros, A., Robbins, P. F., Zheng, Z., Dudley, M. E., Feldman, S. A., Yang, J. C., Sherry, R. M., et al. (2013) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3182829903 · Cited by 1,148
Self-citationB16 as a Mouse Model for Human Melanoma
Overwijk, W. W., & Restifo, N. P. (2000) · Current Protocols in Immunology · doi:10.1002/0471142735.im2001s39 · Cited by 434
CD8+ T cell efficacy in vaccination and disease
Appay, V., Douek, D. C., & Price, D. A. (2008) · Nature Medicine · doi:10.1038/nm.f.1774 · Cited by 393
Single and Dual Amino Acid Substitutions in TCR CDRs Can Enhance Antigen-Specific T Cell Functions
Robbins, P. F., Li, Y. F., El-Gamil, M., Zhao, Y., Wargo, J. A., Zheng, Z., Xu, H., Morgan, R. A., Feldman, S. A., Johnson, L. A., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.9.6116 · Cited by 383
Self-citationThe Makings of a Tumor Rejection Antigen
Gilboa, E. (1999) · Immunity · doi:10.1016/s1074-7613(00)80101-6 · Cited by 381
Metadata
- Authors
- Zeh, H. J., Perry-Lalley, D., Dudley, M. E., Rosenberg, S. A., & Yang, J. C.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 1999-01
- Volume
- 162
- Issue
- 2
- Pages
- 989-994
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1643293176
- Cited by
- 376
- References
- 14
- FWCI
- 6.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: High Avidity CTLs for Two Self-Antigens Demonstrate Superior In Vitro and In Vivo Antitumor Efficacy. https://app.cochat.ai/papers/10.4049/jimmunol.162.2.989
- The paper
- Zeh, H. J., Perry-Lalley, D., Dudley, M. E., Rosenberg, S. A., & Yang, J. C. (1999). High Avidity CTLs for Two Self-Antigens Demonstrate Superior In Vitro and In Vivo Antitumor Efficacy. The Journal of Immunology. https://doi.org/10.4049/jimmunol.162.2.989
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.